Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01198067 · ClinicalTrials.gov registry record · Phase 1
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01198067: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01198067 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01198067, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of pomalidomide in treating patients with Waldenstrom macroglobulinemia that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Pomalidomide may stimulate the immune system in different ways and stop cancer cells from growing.
Interventions
- DRUG Pomalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-10-06 |
| Est. Completion | 2025-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01198067
The ClinicalTrials.gov registry entry for NCT01198067 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pomalidomide is the first listed.
NCT01198067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01198067 about?
NCT01198067 is a clinical study titled "Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia". This phase I trial studies the side effects and best dose of pomalidomide in treating patients with Waldenstrom macroglobulinemia that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Pomalidomide may stimulate the immune system in different ways a...
What is the current status of trial NCT01198067?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2010-10-06. Estimated completion is 2025-05-02.
What interventions are being tested in trial NCT01198067?
The interventions under investigation include: Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT01198067?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.